Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
Int J Mol Sci. 2020 Aug 5;21(16):5619. doi: 10.3390/ijms21165619.
Antimicrobial resistance is an important issue for global health; in immunocompromised patients, such as solid organ and hematological transplant recipients, it poses an even bigger threat. Colonization by multidrug-resistant (MDR) bacteria was acknowledged as a strong risk factor to subsequent infections, especially in individuals with a compromised immune system. A growing pile of studies has linked the imbalance caused by the dominance of certain taxa populating the gut, also known as intestinal microbiota dysbiosis, to an increased risk of MDR bacteria colonization. Several attempts were proposed to modulate the gut microbiota. Particularly, fecal microbiota transplantation (FMT) was successfully applied to treat conditions like infection and other diseases linked to gut microbiota dysbiosis. In this review we aimed to provide a look at the data gathered so far on FMT, focusing on its possible role in treating MDR colonization in the setting of immunocompromised patients and analyzing its efficacy and safety.
抗微生物药物耐药性是全球健康的一个重要问题；在免疫功能低下的患者中，如实体器官和血液系统移植受者，它构成了更大的威胁。耐多药（MDR）细菌的定植被认为是随后感染的一个强烈危险因素，特别是在免疫系统受损的个体中。越来越多的研究将肠道中某些占据主导地位的分类群（也称为肠道微生物失调）引起的失衡与 MDR 细菌定植的风险增加联系起来。已经提出了几种调节肠道微生物群的方法。特别是，粪便微生物群移植（FMT）已成功应用于治疗感染和其他与肠道微生物失调相关的疾病。在这篇综述中，我们旨在提供迄今为止关于 FMT 的研究数据，重点关注其在治疗免疫功能低下患者中 MDR 定植方面的可能作用，并分析其疗效和安全性。
